Atlassian uses cookies to improve your browsing experience, perform analytics and research, and conduct advertising. Accept all cookies to indicate that you agree to our use of cookies on your device. Atlassian cookies and tracking notice, (opens new window)
/
PHUSE Stakeholder Review of ISRCTN Results System Prototype
Updated Oct 01

    PHUSE Stakeholder Review of ISRCTN Results System Prototype

    Background Overview

    The International Standard Randomised Controlled Trial Number registry (ISRCTN) recently released information for public review and comment regarding the new registry they are working on, and the results system prototype is open for review until the end of September.

    The key principles of this results system is to comply with the World Health Organisation data requirements and UK clinical trial regulations, making results submission as easy as we can and provide flexibility for different study designs. Also to help researchers submit accurate and complete data, along with ease of access to this information and re-using the results. 

    Our Collective Purpose to Connect, Share, Advance

    PHUSE has established itself as a key industry voice to regulatory agencies and standards organisations, including the FDA, EMA, and CDISC. We highly value these partnerships. Our global community comprises subject-matter experts from diverse areas within healthcare, and participation in this initiative presents a valuable opportunity to help shape the future of clinical trials.

    ISRCTN will use the feedback you share to implement all necessary revisions to the results system prototype. The more feedback we receive, the better the evolution process for this system. Diverse opinions are encouraged and will play a key part in shaping the clinical trial registration process.

    Making a Difference to Drive Forward the Clinical Trial Landscape

    Making a Difference to Drive Forward the Clinical Trial Landscape

    Building upon our successful submission to provide feedback on new guidance to accompany the MHRA’s updated clinical trials regulations and how it is written, this PHUSE project seeks to obtain and collate stakeholder feedback regarding the ISRCTN results system prototype ahead of the deadline to provide comments (PHUSE submission to ISRCTN due end of September 2025). All responses will be anonymous. There will also be opportunities throughout the review period to join an open discussion about providing flexibility in the way members share their feedback.

    Project Leads

    Email 

    Devaki Thavarajah, Independent

    devaki.thavarajah@phuse.global

    Lucy Marks, PHUSE Senior Project Coordinator

    lucy@phuse.global

    Current Status (Updated Quarterly) 

    • Feedback collected and submitted to ISRCTN

    Objectives & Deliverables

    Timelines

    ISRCTN feedback.

    September 2025

    Welcome to the PHUSE Advance Hub

    WORKING GROUPS
    Results will update as you type.
    • Working Groups
      • Data Transparency
        • Anonymization of Imaging Data
        • Educate the General Population on Data Privacy and Data Sharing
        • EU CTR Implementation
        • Internal Clinical Study Data Sharing Process
        • Patient Data Return
        • PHUSE Stakeholder Review of UK MHRA Clinical Trials Regulation Guidance
          • PHUSE Stakeholder Review of ISRCTN Results System Prototype
        • The Value of Plain Language Summaries of Trial Results
      • Data Visualisation & Open Source Technology
      • Emerging Trends & Innovation
      • Nonclinical Topics
      • Optimizing the Use of Data Standards
      • pharmaverse
      • Real World Evidence
      • Risk Based Quality Management
      • Safety Analytics
    • Hot Topics
    • Useful Information
    • Deliverables
    • Working Groups Events
    • Working Groups Report – Q3 2025
    • Working Groups Archive
    • Working Groups Events Archive

      You‘re viewing this with anonymous access, so some content might be blocked.
      {"serverDuration": 11, "requestCorrelationId": "567ee8885e0c453c9fb64fc3eda61fbb"}